Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01NJT
|
|||
| Former ID |
DCL000526
|
|||
| Drug Name |
Esreboxetine
|
|||
| Synonyms |
(S,S)-reboxetine; 98819-76-2; UNII-L8S50ZY490; PNU-165442G; L8S50ZY490; Norebox; Davedax; Solvex; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine; (2S)-2-[(S)-2-ethoxyphenoxy(phenyl)methyl]morpholine; (2S)-2-[(S)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine; Prolift; Esreboxetine [USAN:INN]; Esreboxetine (USAN/INN); (S,S)-( )-Reboxetine; S-Reboxetine; PNU 165442g; 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate; Tocris-1982; NCGC00025335-01; SCHEMBL34534; Reboxetine mesylate; (+-)-(2R*)-2-((alphaR*)-alpha-(o-Ethoxyphenoxy)benzyl)morpholine; (S,S)-Reboxetine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Fibromyalgia [ICD-11: MG30.01; ICD-10: M79.7; ICD-9: 729.1] | Discontinued in Phase 2 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H23NO3
|
|||
| Canonical SMILES |
CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3
|
|||
| InChI |
1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1
|
|||
| InChIKey |
CBQGYUDMJHNJBX-OALUTQOASA-N
|
|||
| CAS Number |
CAS 98819-76-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8189987, 11114256, 14776713, 14801082, 24723456, 43122598, 46504845, 50065436, 50168465, 57315782, 85177295, 85753305, 96026020, 104046804, 104334847, 126650576, 126683279, 134338008, 135253190, 135785545, 137001349, 142214143, 160698609, 160963582, 163213628, 177749680, 178101510, 179338235, 198950509, 198973023, 223519262, 223686602, 226420981, 241124852, 241169861, 246640544
|
|||
| ChEBI ID |
CHEBI:125535
|
|||
| SuperDrug ATC ID |
N06AX18
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Norepinephrine transporter (NET) | Target Info | Blocker | [2] |
| Panther Pathway | Adrenaline and noradrenaline biosynthesis | |||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | |||
| WikiPathways | Monoamine Transport | |||
| NRF2 pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040151) | |||
| REF 2 | Pfizer. Product Development Pipeline. March 31 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.